# Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia

> **NCT00604760** · PHASE2 · UNKNOWN · sponsor: **Memory Pharmaceuticals** · enrollment: 160 (estimated)

## Conditions studied

- Cognitive Impairment Associated With Schizophrenia

## Interventions

- **DRUG:** MEM 3454
- **DRUG:** MEM 3454
- **DRUG:** MEM 3454
- **DRUG:** Placebo for MEM 3454

## Key facts

- **NCT ID:** NCT00604760
- **Lead sponsor:** Memory Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-12
- **Primary completion:** 2009-02
- **Final completion:** —
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2008-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00604760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00604760, "Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00604760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*